Objective: Vasomotor symptoms (VMS, ie, hot flashes or night sweats) are reported by many, but not all, women. The extent to which VMS are genetically determined is unknown. We evaluated the relationship of genetic variation and VMS.
than 7 years for more than half of women, and 10% of women report having VMS 12 years after the final menstrual period. 4, 5 Ethnicity (African American [AA] vs white), greater body mass index (BMI), lower education level, current smoking, anxiety, and depressive symptoms are associated with an increased risk for frequent VMS. 1 The extent to which VMS are genetically determined is unclear. Genome-wide association studies (GWAS), which are studies of common genetic variation across the entire human genome, identify genetic associations with observable traits. 6 In GWAS, each person's complete chromosomal deoxyribonucleic acid is scanned by machines that quickly survey each person's genome for strategically selected markers of genetic variation called singlenucleotide polymorphisms (SNPs). 7 GWAS can provide valuable clues about genomic function and pathophysiologic mechanisms. 6 GWAS regarding VMS have never been performed among US women. Candidate gene studies suggest that genetic variants may be associated with VMS, including SNPs in estrogen receptor genes and the estrogen metabolism pathway (cytochrome P450 [CYP] CYP1A1, CYP1A2, CYP1B1, and CYP19A1, catechol-O-methyltransferase [COMT], 17-betahydroxysteroid dehydrogenase [17HSD] , and sulfotransferase A1 [SULT1A1] genes). [8] [9] [10] [11] [12] [13] [14] [15] [16] Other candidate gene studies have suggested associations of drug metabolism-related SNPs 17, 18 and serotonin transporter SNPs 19 with VMS. Another candidate gene study suggested associations between genes that control angiogenesis (endothelial nitric oxide synthase [eNOS] and hypoxia inducible factor-1 alpha [HIF1a]) and VMS. 20 Because the pathophysiology of VMS is not well understood, and because GWAS does not require a priori hypotheses regarding associations, GWAS is an invaluable tool to help fill knowledge gaps regarding the pathophysiology of VMS.
The goal of this study was to evaluate the relationship of genetic variation (assessed by GWAS) and VMS in the Women's Health Initiative Study, which collected GWAS data and information regarding VMS in several independent cohorts of postmenopausal women. 21 We hypothesized that we would find multiple genetic variants to be associated with VMS. Elucidation of these variants may lead to new insights into the biological pathways involved in VMS, which are poorly understood. By using a meta-analytic approach to combine GWAS that span multiple ethnic groups (a trans-ethnic metaanalysis), 22 we found that genetic variation in the tachykinin receptor 3 gene (TACR3), which encodes the receptor for neurokinin B (NKB), was associated with VMS. NKB mRNA-expressing neurons are located predominantly in the infundibular nucleus and the anterior hypothalamic area. 23 In humans, NKB neurons co-localize with the gonadotropin-releasing hormone tract in the infundibular stalk, and the NKB pathway is implicated in pubertal development and hypogonadatropic hypogonadism. 23 21, 26 Participants were postmenopausal women aged 50 to 79 years at baseline, free from serious cardiac, pulmonary, renal, and hepatic conditions, with at least 3 years' life expectancy. The WHICTs performed randomized controlled trial evaluation of three distinct interventions: a low-fat eating pattern, menopausal hormone therapy (HT), and calcium plus vitamin D supplementation. 21 The WHI-OS was designed to provide information about disease risk factors, including cancer, cardiovascular disease, and fractures. 21 The combined studies enrolled 161,808 participants (93,676 in the WHI-OS and 68,132 in the WHI-CTs). The WHI Hormone Therapy trials did not exclude women on the basis of having severe VMS, but they excluded women who did not wish to forgo the use of personal menopausal HT. 21 There were several independent GWAS studies conducted within the WHI study: (1) 27 We used all available GWAS data from all three studies, the characteristics of which are shown in Table 1 .
Genotyping was performed using baseline blood samples collected at the time of enrollment. Of the 22,413 total women for whom genotyping data were available in all three GWAS studies combined, data from 21,753 passed quality control criteria, including minimal genotyping efficiencies and no near relatives (see Supplemental Digital Content 1, http://links.lww. com/MENO/A193 for details). Of these women, information regarding baseline self-reported VMS was available for 20,482 women. Of these 20,482 women, information regarding primary analysis covariates was missing for 2,787 women. Therefore, our total analytic sample consisted of 17,695 participants from three ethnic groups (GARNET non-Hispanic European n ¼ 3,282; SHARe AA n ¼ 6,732 and SHARe Hispanic n ¼ 2,778; and WHIMSþ non-Hispanic European n ¼ 4,903) (Fig. 1) .
Participants were asked to complete baseline self-assessment questionnaires. Weight and height were measured at baseline visit with standardized protocols. BMI was calculated as body weight in kilograms (kg) divided by the square of height in meters.
Each institution obtained human subjects committee approval. Each participant provided written informed consent.
or night sweats). Hot flashes and night sweats were assessed as individual symptoms on the symptom checklist. 3, 28 Primary exposure: genotyping For SHARe, genome-wide SNP genotyping was performed using the Affymetrix Genome-wide Human SNP Array 6.0 (Affymetrix, Inc, Santa Clara, CA). [29] [30] [31] An ND-8000 spectrophotometer was used to quantitate genomic DNA. DNA quality was assessed using gel electrophoresis. Affymetrix Genotypic Console software was used to process data for genotype calling by the Birdseed calling algorithm version 2.0 (Affymetrix, Inc). 29 For GARNET, genotyping was performed with the Illumina Human Omni Quad 1.0 M chip (Illumina, Inc., San Diego, CA). 31 WHIMSþ used the Illumina Omni Express Array.
All three substudies were imputed to the same 1000 Genomes reference panel. Before imputation, we excluded data from samples with low genotyping efficiency (sample call rates <95% for SHARe, <98% for GARNET, and <97% for WHIMSþ); SNP assays with locus call rates <90% for SHARe and <98% for GARNET and WHIMSþ; and SNPs that deviated from Hardy-Weinberg equilibrium (P value threshold <1 Â 10 À6 for SHARe and <1 Â 10 À4 for GARNET (version 1.0, Ann Arbor, MI 34, 35 ). All SNPs in the final analytic dataset were imputed, including those that had been directly genotyped. Any SNP whose postimputation minor allele frequency was <0.01 when averaged across the studies, or that had an imputation quality R 2 measure of <0.01, was removed. Data from genetically related individuals were excluded. Allelic R 2 , the squared correlation between the imputed allele dosage with the highest posterior probability and true allele dosage, is a measure of imputation accuracy. 36 An SNP was required to meet the minimal thresholds in all three component studies to be included in the meta-analysis. In total, 19,335,715 SNPs met inclusion criteria in at least one of the studies; 11,078,977 SNPs were available for analysis across all of the studies. A detailed description of the imputation and harmonization effort of the WHI GWAS data is available. 37 
Other covariates
Baseline self-report questionnaires were used to gather information regarding age, race/ethnicity, education, income, cigarette smoking, alcohol intake, physical activity, [38] [39] [40] years since menopause, and oophorectomy. Clinic staff examined the labels of drug containers to collect information regarding medication use.
Statistical analysis
In each separate study, and subsequently in the metaanalysis of all the studies, we analyzed associations between genetic variants and VMS using additive models. In the primary analyses, ever experiencing VMS was categorized as a binary (yes vs no) variable. Principal components were calculated with R using a subset of 5,665 SNPs and all nonduplicate samples across WHI GWAS studies. We used the first 10 principal components as covariates in each of these analyses to adjust for ethnic differences between participants that remained after separating the samples based on selfreported ethnicity. 41 We included the following covariates: bilateral oophorectomy, age at baseline, smoking (never/past/current), alcohol intake (drinks/d, continuous), physical activity (total metabolic equivalents [METs]/wk), population structure (principal components 1-10), BMI (continuous), education (0-8 y, some high school, high school diploma, some school after high school, college degree or higher), income (total annual household income <$20,000, $20,000-$49,999, >$50,000), and menopausal estrogen therapy use (ever use, yes/no).
In a secondary analysis, we repeated the analyses in the subset of women who reporting never having used menopausal HT because HT could mask VMS.
For the meta-analysis, we used R version 3.2.2. 42 The effect size for each SNP from each of the sample datasets was estimated using inverse variance fixed-effects meta-analysis using rmeta package for R version 2.16 (Vienna, Austria). 42, 43 As part of our quality control, we plotted the quantilequantile plot (q-q plot) of the test statistics as compared with their expected values under the null to determine whether our adjustments for study and ethnic differences were effective. 44, 45 As we expected a small number of significant results (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , we removed the 14 most significant results before producing the q-q plot.
RESULTS
At baseline, the mean age of participants was 63.8 years, mean BMI was 29.7 kg/m 2 , 9.6% were current smokers, and 39.3% of participants reported current use of menopausal HT (Table 2) . Thirty-eight percent of participants were AA, 16% were Hispanic, and 46% were non-Hispanic European ancestry.
At baseline, 69% of participants reported ever experiencing VMS. Sixty-three percent of participants of non-Hispanic European ancestry experienced VMS, compared with 77% of AA participants (P < 0.001 vs participants of non-Hispanic European ancestry) and 68% of Hispanic participants (P < 0.001 vs participants of non-Hispanic European ancestry).
After removal of the 14 most significant results, q-q plot of the test statistics as compared with the expected distribution suggests that the likelihood of substantial hidden population substructure or differential genotype calling between cases and controls was unlikely (l ¼ 0.9987071) (Supplemental Fig. 1 , Supplemental Digital Content 1, http://links.lww. com/MENO/A193).
The Manhattan signal plot is a genome-wide plot of Àlog10 of the P value for the SNP-phenotype association versus chromosomal position. 46 That is, the association statistics are shown as Àlog10 of the P value; a P value of 0.01 would be plotted as ''2'' on the y axis. The Manhattan signal plots show the statistical significance of SNP-VMS associations versus chromosomal position for all genotyped SNPs for each of the four separate GWAS ( Fig. 2A-D) . In the individual studies, three SNPs reached the P value threshold of 5 Â 10 À8 , all of them in the SHARe-AA study: rs75699757 and rs11518608 on chromosome 11, and rs148680409 on chromosome 3 (Fig. 2B) . The odds ratios [ORs] for VMS were statistically significantly higher for rs75699757 (OR 1.98) and for rs11518608 (OR 1.07) in SHARe, indicating that the minor allele was positively associated with risk of VMS; in contrast, the minor alleles of these two SNPs were inversely associated with VMS in the SHARe-HA and WHIMSþ studies ( Table 3 ). The opposite directions of the ORs across the individual studies account for the lack of statistically significant association of these two SNPs with VMS in the meta-analysis. Although rs148680409 passed the initial quality control and was associated with a 7.47-fold higher odds of VMS in the SHARe-AA study, this SNP did not pass the quality control criteria for the meta-analysis. SNPs on chromosome 4 were not associated with VMS in the individual studies, even in SHARe, which had the largest sample size.
In the Manhattan signal plot for the meta-analysis (Fig. 2E) , only the locus on chromosome 4 exceeds genome-wide significance. After adjustment for bilateral oophorectomy, age, smoking, alcohol intake, physical activity, population structure, BMI, education, income, and menopausal HT use,
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14 SNPs were associated with increased odds of VMS at a P value threshold <5 Â 10 À8 (Table 3 ). The regional Manhattan plot provides a detailed view of the SNPs on chromosome 4 that were significantly associated with VMS (Supplemental Fig. 2 , Supplemental Digital Content 1, http://links.lww.com/MENO/ A193). These 14 SNPs are located within the same region of chromosome 4, the gene for TACR3. Per allele, the SNPs were associated with 1.20-to 1.83-fold higher odds of VMS.
The magnitudes of associations were consistent in each individual study. Although the GARNET substudy was enriched with women who had cardiovascular disease and/ or diabetes, the magnitudes of associations among the GAR-NET substudy participants were similar to those of the other substudies.
The linkage disequilibrium (LD) plot (Fig. 3) shows the strength of the associations, the LD pattern (r 2 estimates), and the position of the associated SNPs relative to the most strongly associated SNP (rs74827981, represented by a purple circle) and the genes in the region (LocusZoom 47 ). The SNPs that we found to be associated with VMS are clustered tightly within the region of the TACR3 gene, and are not in LD with other SNPs found in other genes within the 3Mb region.
In secondary analyses designated a priori, we repeated the analyses among participants who had never used HT. Among the HT never users, the strongest signals and corresponding ORs were similar to those of the main analysis (Supplemental Table 3 , Supplemental Digital Content 1, http://links.lww. com/MENO/A193).
To facilitate comparison of our results with previous and future studies, we provide the rs numbers and allele frequencies corresponding to the University of California Santa Cruz (UCSC) genome browser 48 chromosomal position of each of the 14 SNPs that met the P value threshold <5 Â 10 À8 (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/MENO/A193). Supplemental Table 2 (Supplemental Digital Content 1, http://links.lww.com/ MENO/A193) displays the observed allele frequencies for the 14 SNPs that were associated with higher odds of VMS.
DISCUSSION
To our knowledge, this is the first published GWAS study to focus on genetic variation in relation to VMS. In this transethnic meta-analysis of several studies, we identified several SNPs that were associated with experiencing hot flashes. The SNPs that were significantly associated with hot flashes at P < 5 Â 10 À8 were all located on chromosome 4 in the intronic regions of the TACR3 gene. TACR3 encodes the NK3R receptor (NK3R). NKB, a member of the tachykinin Table displays the results that were statistically significant (P value threshold <5 Â 10 À8 ) in the meta-analysis of data from all three genome-wide association study (GWAS) studies and/or in the individual studies. Odds ratio (OR) is expressed as allelic OR (SE). Reference group is ''never had vasomotor symptoms.'' Adjusted for bilateral oophorectomy, age, smoking, alcohol intake, physical activity, population structure, body mass index, education, income, and menopausal estrogen therapy use. GARNET study denotes the Genome-Wide Association Studies of Treatment Response in Randomized Clinical Trials cohort of women of non-Hispanic European ancestry. family of peptides, preferentially binds to NK3R. 23 The metaanalysis combined studies of women with different ethnicities. Because regions of high LD (haplotype blocks) will vary by ethnicity, this trans-ethnic approach to meta-analysis can increase statistical power and narrow the region that should be considered for fine-mapping. 22 The effect sizes (ORs) were very similar across racial/ethnic groups, suggesting a relatively ancient origin of the mutation. Statistical power was greatest in European Americans, which can be at least partially accounted for by the differences in minor allele frequencies among the racial/ethnic groups.
There are no previous GWAS studies of hot flashes or hot flushes posted in the GWAS Catalog (https://www.ebi.ac.uk/ gwas/), although age at menarche has been associated with upstream gene variants of TACR3 in a prior GWAS. 49 None of the SNPs that were associated with VMS in the current study produced any search results in the GWAS catalog, highlighting that our research question is novel.
The associations that we observed between genetic variation in NKB pathway genes and hot flashes are biologically plausible. The strongest evidence comes from a recent randomized double-blind placebo-controlled crossover study of healthy women, demonstrating that the infusion of NKB induces hot flashes. 50 Other lines of evidence also implicate a role for NKB in VMS. First, colocalization studies support physiologic interaction between the NKB pathway and gonadotropin pathways. For example, NKB and estrogen receptor alpha messenger RNA are co-expressed in the human infundibular nucleus 23 and the descending gonadotropin-releasing hormone tract that courses through the infundibular stalk to the neurohypophysis is exposed to dense NKB fiber plexuses. 51 In rats, monkeys, and sheep, NKB fibers project from the arcuate nucleus (the area corresponding to the human infundibular nucleus) to the median eminence, a site with dense gonadotropin-releasing hormone terminals. 23 Second, menopause and/or oophorectomy are associated with changes in NKB gene expression in human and animal studies. For example, NKB gene expression in the human infundibular nucleus increases after menopause, and in monkeys and rats, ovariectomy induces similar increases in NKB gene expression that are reversed by estradiol therapy. 23, 24 Compared with premenopausal women, postmenopausal women have hypertrophy of neurons expressing NKB. 23 Third, in humans, inactivating mutations of the NKB gene (TAC3) and TACR3 induce hypogonadotropic hypogonadism. For example, in humans, TAC3 and TACR3 inactivating mutations are associated with absent pubertal development as well as low circulating serum luteinizing hormone and gonadal steroid levels. 23, 25 In rhesus monkeys, intervention to slow the frequency of gonadotropin-releasing hormone pulses can reproduce the pattern of low serum luteinizing hormone seen in humans with TAC3 and TACR3 mutations, suggesting that women with deficits in NKB/NK3R signaling have changes in the pattern of gonadotropin-releasing hormone pulses. 23 Finally, the infusion of a potent selective NK3R agonist (senktide) into the median preoptic nucleus of the rat markedly reduces core body temperature, suggesting that hypertrophy of NKB neurons characterizing postmenopausal women could be involved in the biology underlying menopausal hot flashes. 23, 52 On the National Institutes of Health Common Fund's Genotype-Tissue Expression (GTEx) website (https://com monfund.nih.gov/GTEx/index), the highest gene expression (reads per kilobase of transcript per million mapped reads) for TACR3 is located in the hypothalamus, followed by the amygdala (http://www.gtexportal.org/home/gene/TACR3). 
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Searches for the TACR3 SNPs associated with VMS in the current study produced no results in GTEx.
The This study has potential limitations. Although it would be interesting to investigate gene-gene or gene-environment interactions, we do not have sufficient power with the current sample size to carry forward these analyses. The variants identified are noncoding and have not been implicated as regulatory. As is the case with all GWAS studies, genetic variation in intronic regions could indicate that SNPs exert effects on splicing or regulation of transcription or methylation sites of other genes, or they could affect translation, induce posttranslational modifications, lead to changes in mRNA stability, or affect ligand binding. 53 Alternatively, the identified SNPs may not be causal, but may instead be tightly linked with the underlying true causal variants.
It is likely that there are still rare variants of moderate effect as well as common variants of small effect that we have not detected. By combining studies across ethnic groups using meta-analysis, we down-weight the importance of ethnicspecific association. In addition, each of the cohorts were genotyped using SNP platforms that include approximately 1 million SNPs, which means that many SNPs and singlenucleotide variations are not directly genotyped, that is we could fail to discover a rare variant (or even a common variant) that is not included in the SNP array. There are, however, two related points that ameliorate this concern. First, LD leads to high correlation between the variants at an SNP that was genotyped and the variants of loci that were not genotyped. Second, based on this principle of LD, our densely genotyped marker sets, and well-characterized reference panels, we imputed 10-fold more SNPs than were directly genotyped.
Although VMS were self-reported in this study, self-reporting of VMS reflects clinical practice. Also, because individuals are unaware of their genotypes, self-report should not be differentially biased between TACR3 variant carriers and those individuals homozygous for the major allele. The numbers of women with severe VMS at baseline were too low to allow us to reliably examine genetic variation in relation to the severity of VMS. It is possible that women with severe VMS did not consent for inclusion in the study. Strengths of this study include the large sample size, ethnic diversity of participants, and detailed information regarding potential confounders. The GWAS approach provides an unbiased source of information regarding previously unknown functional pathways.
We are encouraged by the GWAS results and our bioinformatics analyses, which lend support to the hypothesis of the NKB pathway as a target for the treatment of VMS symptoms, but confirmation of these results is necessary before clinical implications can be made. Necessary steps in testing this hypothesis include replication and fine-mapping of TACR3, perhaps by targeted sequencing followed by in-silico annotation, characterization of variant function using epigenetic and expression data, and ultimately functional studies using cell lines, human tissue, and isogenetic or mouse models. 54 
CONCLUSIONS
In conclusion, several SNPs located in the area coding for TACR3 were associated with increased odds of VMS at a P < 5 Â 10 À8 . Per allele, each of these SNPs was associated with 1.4-to 1.6-fold higher odds of VMS. The ORs were consistent in several cohorts from diverse ethnic groups. To our knowledge, the present study is the first GWAS of VMS. Ultimately, elucidation of the mechanisms responsible for VMS could yield novel therapies for hot flashes. Our results should inform the study of biological pathways responsible for VMS. Interrelations between genetic markers and other known environmental risk factors for VMS require study.
